It’s a great idea to invest in us – and here’s why
- Poised for long-term growth; building on attractive mega trends in Life Science, Healthcare and Electronics
- Resilient and high-quality cashflow profile; reliable cash generation leveraging multi-industry set up
- Strong M&A track record enhanced by rapid deleveraging
- Bringing innovation faster to patients and customers, contributing to their sustainability efforts
Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany, and Siemens enter Strategic Partnership
Memorandum of Understanding signed to drive digital transformation through strategic projects across all three business sectors
2024/09/16
-
Press Releases
Merck KGaA, Darmstadt, Germany Unveils New MAVENCLAD® Four-Year ...
The company today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine) tablets in relapsing multiple sclerosis.
2024/09/12
-
Press Releases
MilliporeSigma Launches Single-Use Reactor Designed to Accelerate ADC Manufacturing
MilliporeSigma launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs).
2024/09/10
Share Price
Check Share PriceShare Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.
Financials
Read MoreFinancials
Our Financial Reporting Center offers you the opportunity to select from financial data on an annual or quarterly basis.